BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/17/2022 5:34:40 AM | Browse: 93 | Download: 193
Publication Name World Journal of Clinical Oncology
Manuscript ID 69253
Country/Territory Argentina
Category Oncology
Manuscript Type Retrospective Cohort Study
Article Title First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study
Manuscript Source Unsolicited Manuscript
All Author List Agustín Falco, Mariano Leiva, Albano Blanco, Guido Cefarelli, Andrés Rodriguez, Juan Melo, Federico Cayol, Manglio Miguel Rizzo, Alejandro Sola, Hernán Rodríguez Montani, Matías Chacon, Diego Enrico and Federico Waisberg
Funding Agency and Grant Number
Corresponding Author Agustín Falco, MD, Staff Physician, Department of Medical Oncology, Head and Neck Unit, Alexander Fleming Cancer Institute, Cramer 1180, Buenos Aires 1428, Argentina. afalco@alexanderfleming.org
Key Words Recurrent and/or metastatic head and neck cancer; TPEx schema; Cetuximab; Docetaxel; Cisplatin; First-line
Core Tip We evaluated the safety and efficacy of the combination platinum, taxanes, and cetuximab scheme as a first-line therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck in a real-world setting. Among the 24 patients included, the median progression-free survival was 6.9 mo (95% confidence interval: 6.5-7.3), and the overall survival rate at 12 mo was 82.4%, which was consistent with previous clinical trials. Patients with documented tumor response showed statistically better progression-free survival than those with disease stabilization or progression (P = 0.034). The combination platinum, taxanes, and cetuximab regimen was adequately tolerated by most of the analyzed patients, as the incidence of grade 3-4 adverse events was surprisingly lower than expected (25%).
Citation Falco A, Leiva M, Blanco A, Cefarelli G, Rodriguez A, Melo J, Cayol F, Rizzo MM, Sola A, Rodríguez Montani H, Chacon M, Enrico D, Waisberg F. First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study. World J Clin Oncol 2022; 13(2): 147-158
Received
2021-06-22 22:03
Peer-Review Started
2021-06-22 22:07
To Make the First Decision
Return for Revision
2021-07-16 05:52
Revised
2021-08-04 02:34
Second Decision
2022-01-15 02:42
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2022-01-17 05:34
Articles in Press
2022-01-17 05:34
Publication Fee Transferred
Edit the Manuscript by Language Editor
2021-12-19 01:32
Typeset the Manuscript
2022-02-16 13:49
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com